Ask AI

Identifying and Managing Treatment-Related Adverse Events in TGCT

Video
This activity is available for 0.25 CME/CE credit(s).

Released: August 25, 2026

Expiration: February 24, 2027

See Activity Collection

In this video-based module, expert faculty reviews the safety profiles of the FDA-approved CSF1R inhibitors pexidartinib and vimseltinib for tenosynovial giant cell tumor (TGCT). The faculty also highlights common and clinically important adverse events, including hepatotoxicity, periorbital edema, rash, pruritus, gastrointestinal toxicities, and laboratory abnormalities, as well as differences between the agents. Patient counseling, laboratory monitoring, supportive care, treatment interruption, dose reduction, and permanent discontinuation strategies are also addressed to help healthcare professionals balance treatment efficacy with safety and quality of life in patients with TGCT.

TRAEs in TGCT

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with TGCT do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Which of the following monitoring plans would you implement for a patient starting pexidartinib based on current recommendations?